» Articles » PMID: 10872744

The Heme Oxygenase System and Its Functions in the Brain

Overview
Specialty Cell Biology
Date 2000 Jun 29
PMID 10872744
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The heme oxygenase (HO) system was identified in the early 1970s as a distinct microsomal enzyme system that catalyzes formation of bile pigments (Maines and Kappas, 1974). Up to the early 1990s the system was considered only as a "molecular wrecking ball" (Lane, 1998) for degradation of the heme molecule and production of toxic waste products, CO and bile pigments. For those years, the HO system remained relatively unknown to the research community. In a rather short span of the past 10 years following the discovery of high levels of a second form of the enzyme, HO-2, in the brain, suggesting that "heme oxygenase in the brain has functions aside from heme degradation" (Sun et al., 1990); concomitant with finding that another toxic gas, NO, is a signal molecule for generation of cGMP (Ignarro et al., 1982), the system was propelled into main stream research. This propulsion was fueled by the realization of the multiple and diverse functions of heme degradation products. Heme oxygenase has now found relevance in all kinds of human pathophysiology ranging from stroke, cancer, multiple sclerosis, and malaria to transplantation and immune response. As it turns out, its potential benefits are mesmerizing investigators in diverse fields (Lane, 1998). The most recent findings with HO-2 being a hemoprotein and potentially an intracellular "sink" for NO (McCoubrey et al., 1997a; Ding et al., 1999), together with the discovery of the third form of the enzyme, HO-3 (McCoubrey et al., 1997b), are likely to insure the widespread interest in the enzyme system in the coming years. The present review is intended to highlight molecular properties of HO isozymes and their likely functions in the brain. Extended reviews of the system are found in Maines (1992, 1997).

Citing Articles

Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease.

Mumtaz I, Ayaz M, Khan M, Manzoor U, Ganayee M, Bhat A Front Aging Neurosci. 2022; 14:977411.

PMID: 36158539 PMC: 9490081. DOI: 10.3389/fnagi.2022.977411.


Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury.

Detsika M, Lianos E Antioxidants (Basel). 2021; 10(1).

PMID: 33418934 PMC: 7825075. DOI: 10.3390/antiox10010060.


Two Faces of Heme Catabolic Pathway in Newborns: A Potential Role of Bilirubin and Carbon Monoxide in Neonatal Inflammatory Diseases.

Osiak W, Watroba S, Kapka-Skrzypczak L, Kurzepa J Oxid Med Cell Longev. 2020; 2020:7140496.

PMID: 32908636 PMC: 7450323. DOI: 10.1155/2020/7140496.


The BACH1/Nrf2 Axis in Brain in Down Syndrome and Transition to Alzheimer Disease-Like Neuropathology and Dementia.

Perluigi M, Tramutola A, Pagnotta S, Barone E, Butterfield D Antioxidants (Basel). 2020; 9(9).

PMID: 32839417 PMC: 7554729. DOI: 10.3390/antiox9090779.


Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials.

Rueda Revilla N, Martinez-Cue C Antioxidants (Basel). 2020; 9(8).

PMID: 32756318 PMC: 7464577. DOI: 10.3390/antiox9080692.